Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer February 26, 2025
Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission February 20, 2025
Photys presents recent data at Keystone Symposia for Proximity-Based Therapeutics on p53-Y220C-BET-bifunctionals that drive death of cancer cells in vitro and in vivo. February 20, 2025
